- |||||||||| Ztalmy (ganaxolone oral) / Marinus, Xcopri (cenobamate) / SK Bio, Fintepla (low-dose fenfluramine) / UCB
Journal: Antiseizure Medications: Advancements, Challenges, and Prospects in Drug Development. (Pubmed Central) - Jun 24, 2025 The review also discusses the development of new potential ASMs, including modifying existing ASMs to improve efficacy and tolerability. Furthermore, we expound on the modulation of ?- aminobutyric acid type A receptor (GABAAR) as a strategy for the treatment of epilepsy and the identification of a GABAAR agonist, isoguvacine, as a potential ASM.
- |||||||||| triamcinolone acetonide topical / Generic mfg., Xcopri (cenobamate) / SK Bio
Review, Journal: Drug-induced subacute cutaneous lupus erythematous from cenobamate: case presentation and review of the literature. (Pubmed Central) - Jun 17, 2025 Given the worsening rash, positive labs, and cenobamate as the only changed drug several months before initial onset, she was diagnosed with drug-induced subacute cutaneous lupus erythematous and her cenobamate was discontinued. To the best of your knowledge, this is the first reported case of a medication in the carbamate family leading to drug induced subacute cutaneous lupus erythematosus.
- |||||||||| Xcopri (cenobamate) / SK Bio
Journal: Cenobamate-associated weight loss (Cenobaweight study). (Pubmed Central) - Jun 13, 2025 Systematic weight assessment should be considered in all patients on CNB, especially with telehealth. Clinicians should rule out contributing etiologies and consider CNB dose reduction if excessive weight loss occurs.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Journal: Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson's disease. (Pubmed Central) - Jun 9, 2025 At follow-up, PD-CTRL showed no significant differences in WOQ-19, motor scales, and neuropsychological tests compared to baseline. OPC improved end-of-dose fluctuations in anxiety/depression, and executive functions/attention, while memory and visuospatial abilities showed little or no significant changes.
- |||||||||| Xcopri (cenobamate) / SK Bio
Journal: Steps towards seizure freedom with the use of Cenobamate. (Pubmed Central) - Jun 8, 2025 This is the first real-world data series that compares the use of CNB in two cohorts of a single centre. One year follow-up seizure freedom rates above 20% can be achieved by a proper patient selection, CNB dose increase and ASM dose reduction, which eventually lead to CNB monotherapy in some cases.
- |||||||||| Xcopri (cenobamate) / SK Bio
Journal: Cenobamate and pregnancy: A-single level 4 epilepsy center experience. (Pubmed Central) - Jun 7, 2025 While our report remains anecdotal and preliminary given the very small sample size, we underscore the importance of pre-conceptual counseling in FCAWE to prevent unintended pregnancies and undesired outcomes, particularly when using ASM with limited data regarding teratogenicity. We also shed light on drug level monitoring during pregnancy.
- |||||||||| Xcopri (cenobamate) / SK Bio
Review, Journal: Potential of cenobamate as a broad-spectrum antiseizure medication. (Pubmed Central) - Jun 5, 2025 Evidence is accumulating regarding the utility of cenobamate in treating primary generalized tonic-clonic (PGTC) and seizures associated with developmental epileptic encephalopathies such as Lennox-Gastaut syndrome and Dravet syndrome. Results from the ongoing cenobamate trial in patients with idiopathic generalized epilepsy will determine the efficacy of cenobamate for the treatment of PGTC seizures.
- |||||||||| Xcopri (cenobamate) / SK Bio
Journal, Real-world evidence: Real-world use of cenobamate in adults: Efficacy and predictors of treatment response. (Pubmed Central) - May 22, 2025 Cenobamate is an efficacious drug. Baseline clinical features of seizure type, lower frequency, fewer failed medications, and clobazam use are associated with treatment response and can inform decisions of trialing cenobamate before considering epilepsy surgery.
- |||||||||| Xcopri (cenobamate) / SK Bio
Clinical, Retrospective data, Journal, Real-world evidence: Efficacy and safety of Cenobamate: a multicenter, retrospective evaluation of real-world clinical practice. (Pubmed Central) - May 12, 2025 Larger studies are required to solidify these findings and better understand the safety profiles of all involved ASMs. Cenobamate is a highly effective and well-tolerated ASM for patients with DRE, offering significant clinical benefits, including improved seizure control and reduced polytherapy.
- |||||||||| Sunosi (solriamfetol) / Axsome Therap, Pharmanovia
Trial completion, Trial completion date, Trial primary completion date: PARADIGM: Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol (clinicaltrials.gov) - Apr 17, 2025 P3, N=346, Completed, Switching to opicapone in patients with suboptimal responses to entacapone may enhance the continuation rate. Recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Dec 2024
- |||||||||| Xcopri (cenobamate) / SK Bio
Journal: Increase of Brivaracetam serum concentration with introduction of Cenobamate. (Pubmed Central) - Apr 16, 2025 New introduction of Cenobamate to a pre-existing antiseizure regimen containing Brivaracetam leads to considerably increases in Brivaracetam, probably related to inhibition of CYP2C19. This needs to be taken into account when interpreting changes in treatment efficacy, but also when relating potential adverse effects to baseline vs. newly introduced treatment.
- |||||||||| Xcopri (cenobamate) / SK Bio
Journal: Cenobamate: A Review in Focal-Onset Seizures. (Pubmed Central) - Apr 14, 2025 The effectiveness and adverse events of cenobamate in real-world studies were consistent with those seen in the clinical studies. Thus, cenobamate continues to represent a useful adjunctive treatment option in adults with uncontrolled focal-onset seizures.
- |||||||||| Xcopri (cenobamate) / SK Bio
Clinical, Journal: Exploring the Effectiveness of Adjunctive Cenobamate in Focal Epilepsy: A Time-Based Analysis. (Pubmed Central) - Apr 10, 2025 Explorative estimates suggested favorable trends for subjects treated with concomitant GABAergics and without SCBs, who seemed to reach baseline seizure count and experience AEs less frequently and later than subjects treated with other concomitant ASMs. Further studies are needed to identify the best combinations of CNB with other ASMs to maximize seizure control and tolerability.
- |||||||||| Sunosi (solriamfetol) / Axsome Therap, Pharmanovia
Trial completion date, Trial termination: Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder (clinicaltrials.gov) - Apr 7, 2025 P4, N=82, Terminated, Further studies are needed to identify the best combinations of CNB with other ASMs to maximize seizure control and tolerability. Trial completion date: Nov 2024 --> Apr 2024 | Recruiting --> Terminated; Study was stopped due to funding limitations.
- |||||||||| Journal: A Case of Aicardi Syndrome with Positive Outcomes Following Hemispherectomy (P10-9.015). (Pubmed Central) - Apr 7, 2025
EEG showed hypsarrhythmia responsive to vigabatrin...Patient trialed on carbamazepine, oxcarbazepine, divalproex, levetiracetam, phenobarbital, phenytoin, clobazam, and topiramate...Medication regimen consisted of oxcarbazepine 900 mg BID, brivaracetam 150 mg BID, cenobamate 200 mg daily, and cannabidiol 2 mL/kg BID...In light of dramatic improvement in seizure frequency and severity, she weaned off multiple antiepileptic medications, now on cenobamate 300 mg and klonopin 0.5 mg daily...Dr. Proteasa has nothing to disclose.
- |||||||||| Xcopri (cenobamate) / SK Bio
Retrospective data, Journal, Monotherapy: Cenobamate Monotherapy for Focal Epilepsy: A Single-Center Retrospective Study. (Pubmed Central) - Apr 7, 2025 The mean seizure frequency on cenobamate was reduced from 4.3 to 0.7 per month; the responder rate (50% reduction in seizure frequency) was achieved at 77%, and 55% of the patients remained seizure-free during the 12-month observation period. Cenobamate monotherapy was found to significantly reduce seizure frequency and achieve high seizure freedom rates and was well tolerated in patients with focal epilepsy, highlighting its promise as an emerging alternative for patients with refractory focal epilepsy.
- |||||||||| Wakix (pitolisant) / Ferrer International, Paragon Biosci, Aculys Pharma, Sunosi (solriamfetol) / Axsome Therap, Pharmanovia
Review, Journal: Management options for excessive daytime sleepiness in patients with obstructive sleep apnea. (Pubmed Central) - Apr 1, 2025 Solriamfetol and pitolisant are wake-promoting agents (WPA) recently approved for use in sleepy OSA patients accepting or refusing OSA treatment...However, it is still uncertain which subgroups of patients should be treated for the symptom of EDS while maintaining a low-risk profile in terms of consequences of OSA on health. Until such data are available, use of WPA in OSA patients should be managed by Sleep Specialists.
- |||||||||| Wakix (pitolisant) / Ferrer International, Paragon Biosci, Aculys Pharma, Sunosi (solriamfetol) / Axsome Therap, Pharmanovia
Journal: Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea (Pubmed Central) - Mar 31, 2025 Regular encouragement to continue conventional OSA therapy should be provided throughout the treatment period.Recommendation 10: Methylphenidate or dextroamphetamine is not currently recommended for OSA-related EDS due to insufficient evidence (no evidence, D).Recommendation 11: Regular monitoring of the efficacy and safety of wake-promoting agents is recommended...Strict monitoring for adverse effects is required during treatment, including the risk of drug dependence, addiction, and cardiovascular events. Caution should be exercised when prescribing these agents to patients with cardiovascular risk factors (3, B).
- |||||||||| Xcopri (cenobamate) / SK Bio
Retrospective data, Journal, Real-world evidence: Real-world effectiveness and tolerability of cenobamate in drug-resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom. (Pubmed Central) - Mar 22, 2025 After 6?months from cenobamate start, 49.3% of patients had their seizures cut by half or more, and 13.6% became seizure-free. A total of 30.9% of patients had an undesirable reaction to cenobamate, mostly mild-to-moderate and resolved; the most frequent were asthenia, dizziness, and somnolence.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Review, Journal: Adjunctive treatment for pediatric focal epilepsy: a systematic review. (Pubmed Central) - Mar 19, 2025 In terms of efficacy and safety, lamotrigine and levetiracetam may be selected preferentially for the adjunctive treatment of focal epilepsy in children and adolescents. However, owing to the limited random clinical trials, our results need to be verified by further studies.
|